What is the recommended regimen for using Efudix (5‑fluorouracil) cream to treat squamous cell carcinoma in situ on the scalp?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Efudix (5-Fluorouracil 5%) for Scalp SCC In Situ

For squamous cell carcinoma in situ on the scalp, apply Efudix 5% cream twice daily for 3-4 weeks, with treatment repeated if needed, as the scalp is specifically noted as a suitable site where 5-FU can be effectively used. 1

Recommended Treatment Regimen

The standard protocol based on British Association of Dermatologists guidelines is:

  • Initial application: Once daily for 1 week, then twice daily for 3 weeks 1
  • Duration: Total of 3-4 weeks 1
  • Repeat if necessary: Treatment can be repeated for partial responses 1
  • Application method: Use a non-metal applicator or glove; wash hands immediately if applied with fingers 2

The FDA label for superficial basal cell carcinomas (similar depth to SCC in situ) recommends continuing treatment for at least 3-6 weeks, potentially extending to 10-12 weeks for complete obliteration 2.

Expected Response and Timeline

You should observe a predictable inflammatory sequence: erythema → vesiculation → desquamation → erosion → re-epithelialization 2. Continue treatment until the erosion stage is reached, then stop 2. Complete healing may take 1-2 months after stopping therapy 2.

Efficacy Evidence

The evidence for 5-FU on the scalp is favorable:

  • 83% complete response rate at 3 months in a large European multicenter RCT 1
  • 67% response at 12 months in another RCT, though this dropped to 48% after recurrences 1
  • 88% clearance rate for lesions <2 cm in a recent 2024 study 3
  • 96% clearance rate as primary therapy in another 2024 study 4

The scalp is explicitly mentioned as a site where 5-FU "can be used even on the scalp" in the guidelines, distinguishing it from problematic sites like the lower leg 1.

Critical Factors for Success

Treatment duration matters significantly. A 2024 multivariate analysis found:

  • ≥4 weeks treatment: 93.2% clearance
  • 2 to <4 weeks: 86.7% clearance
  • <2 weeks: Only 57.1% clearance
  • Shorter duration was significantly associated with treatment failure (OR: 0.26, P=.007) 3

Lesion size also impacts outcomes:

  • Lesions <2 cm: 88.9% clearance
  • Lesions ≥2 cm: 60% clearance (P=.051) 3

Important Caveats

Hyperkeratotic lesions may fail due to poor drug penetration through thick keratin 1. Consider gentle debridement or keratolytic pretreatment if significant hyperkeratosis is present.

5-FU is less effective than PDT (80% vs 93% sustained response at 12 months) but remains a reasonable choice when PDT is unavailable or cost-prohibitive 1, 5. However, 5-FU is more practical than surgery for large lesions and at sites where surgical healing may be problematic 1.

Comparative Context

According to BAD guidelines, for scalp lesions, 5-FU receives a "generally fair choice" rating (score of 3), while PDT is rated higher (score of 2) 1. The guidelines give 5-FU a Strength of Recommendation B with Level of Evidence 1+ 1.

Up to 97% of patients experience at least one adverse event (erythema, pruritus, pain), but these are generally manageable 6. The scalp typically heals well compared to lower extremities.

Monitoring

Follow patients for at least 12 months post-treatment, as recurrences can occur. One study showed recurrence at 8 months in 3.6% of cases 4. If clinical clearance is not evident at 3 months, consider re-treatment or alternative therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.